T 506.862.7512
F 506-869-7484
This email address is being protected from spambots. You need JavaScript enabled to view it.
Dr. Ouellette is currently a Senior Researcher and Founder of the Atlantic Cancer Research Institute and Chair of the R.R. Leger Prostate Cancer/NBHRF Chair in Precision Cancer Research. After completing his bachelors and masters degrees in biochemistry from Université de Moncton, Dr. Ouellette received both his MD and PhD in Molecular and Cellular Biology from Université Laval in 1996. He then completed his residency in Family Medicine from Université de Sherbrooke in 1998. Currently, he is adjunct professor of biochemistry at Université de Moncton and adjunct professor of biology at the University of New Brunswick.
His team is focused on translating biological discovery into clinical application and has active projects in breast, prostate and lung cancer as well as B-cell lymphoma. Current projects include the development of a peptide-based exosome and extra-cellular microvesicle capture technology as a means to identify novel circulating biomarkers for prostate cancer diagnosis. This technology was recently licensed for commercial sales with a US-based company and has led to the creation spin-off biotech company to pursue application development in cancer diagnostics. Another emerging research focus involves using a CRISPR-Cas9 based gene silencing approach to identify therapeutic targets in lung cancer thru a synthetic lethality screen with tumor suppressors deleted on chromosome 3p.
He maintains numerous collaborations within and outside ACRI both with academia and private sector. Collaborations include with researchers at Université de Moncton, Université de Sherbrooke and McGill University as well as with industry partners New England Peptide and Soricimed BioPharma.
He also maintains a clinical practice as director of the Molecular Genetics and Sequencing Laboratory at the Dr Georges L Dumont University Hospital.
